Market Profile: Process FT-NIR for PAT in Pharma and Biopharma - - Spectroscopy
 Home   Mass Spectrometry   ICP-MS   Infrared   FT-IR   UV-Vis   Raman   NMR   X-Ray   Fluorescence  
Home
Magazine
Issue Archive
Subscribe/Renew
Special Issues
Reprints
The Application Notebook
Current Issue
Archive
Submission Guidelines
Training
SpecAcademy
E-solutions
Digital Edition
Subscribe to the Digital Edition
The Wavelength
Subcribe to The Wavelength
Subscribe to the MS E-news
Resources
Market Profiles
Information for Authors
SpecTube
Webcasts
Advertiser services
Contact Us
Columns
Atomic Perspectives
Chemometrics in Spectroscopy
Focus on Quality
Laser and Optics Interface
Mass Spectrometry Forum
The Baseline
Molecular Spectroscopy Workbench

Market Profile: Process FT-NIR for PAT in Pharma and Biopharma

Spectroscopy
Volume 26, Issue 6


Biopharmaceutical and pharmaceutical process FT-NIR vendor share in 2010.
Fourier-transform near-infrared (FT-NIR) spectroscopy continues to be a rapidly growing process analytical technique, particularly in the pharmaceutical and biopharmaceutical industry. The technique offers a number of advantages for online applications, and most of the major NIR instrument vendors now compete in this segment of the market.

FT-NIR spectrometers make use of a simpler mechanical design than dispersive NIR instruments, and therefore provide a more rugged and reliable design that is advantageous in any industrial setting, including pharmaceutical and biopharmaceutical manufacturing. In addition, FT-NIR provides simultaneous analysis of all frequencies in the spectrum range, rather than scanning individual wavelengths. FT-NIR is also capable of much higher resolution than dispersive instruments, which is important in the pharmaceutical and biopharmaceutical industry.

FT-NIR is becoming increasingly popular for process analytical technology (PAT) and other online applications in the pharmaceutical and biopharmaceutical industry, such as monitoring drying and blending processes. The global market for process FT-NIR in the pharmaceutical and biopharmaceutical industry in 2010 was more than $21 million, and it is expected to continue to see annual growth in the mid-teens for the foreseeable future. At least a half dozen instrument vendors are significant competitors in the market.

The foregoing data were extracted from SDi's market analysis and perspectives report entitled Biotech & Pharmaceutical Process Analysis: PAT Instrumentation and More, March 2011. For more information, contact Stuart Press, Vice President, Strategic Directions International, Inc., 6242 Westchester Parkway, Suite 100, Los Angeles, CA 90045, (310) 641-4982, fax: (310) 641-8851, http://www.strategic-directions.com/.

Rate This Article
Your original vote has been tallied and is included in the ratings results.
View our top pages
Average rating for this page is: 1.75
Headlines from LCGC North America and Chromatography Online
Agilent EU - Method Development of Mixed-Mode Solid Phase Extraction for Forensics Appliations
Agilent NA - Method Development of Mixed-Mode Solid Phase Extraction for Forensics Appliations
Biotage EU - Extraction of GHB from Urine Using ISOLUTE® SLE+ Prior to GC/MS
FMS NA - Solid-Phase Extraction and Analysis Of Phosphorus Flame Retardants from Drinking Water
EMD Millipore NA - Water for GC-MS Analysis of VOCs
Source: Spectroscopy,
Click here